Why the study?
Does sacubitril/valsartan improve outcomes compared to enalapril consistently across different etiologies in patients with HFrEF?
Does sacubitril/valsartan improve outcomes compared to enalapril consistently across different etiologies in patients with HFrEF?
The clinical benefit of sacubitril/valsartan over enalapril in HFrEF is consistent regardless of the underlying heart failure etiology.
Supports sacubitril/valsartan use across HFrEF etiologies; confirms consistent benefit in RCT evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Balmforth et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: